1. "Gynecologic Medicine Service"
Formats
  1. Journal Article (1087)
  2. Meeting Abstract (890)
  3. Review (52)
  4. Book Section (46)
  5. Editorial (35)
  6. Guidelines (21)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Gynecologic Medicine Service (2146)
  2. Solid Tumor Oncology Division (2146)
  3. Department of Medicine (2142)
  4. Gynecology Disease Management Team (1846)
  5. GDMT, Medicine (1828)
  6. Surgery (594)

More Groups

People
  1. Carol Aghajanian (607)
  2. Martee Hensley (289)
  3. Nadeem Abu-Rustum (288)
  4. Roisin O'Cearbhaill (271)
  5. Vicky Makker (263)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (41)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (450)
  2. Gynecologic Oncology (418)
  3. International Journal of Gynecological Cancer (154)
  4. Annals of Oncology (116)
  5. Clinical Cancer Research (67)
  6. Cancer Research (55)

More Publications

Publishers
  1. Elsevier Inc. (542)
  2. American Society of Clinical Oncology (489)
  3. Lippincott Williams & Wilkins (181)
  4. American Association for Cancer Research (168)
  5. Oxford University Press (143)
  6. Nature Publishing Group (86)

More Publishers

Results (2146)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group
    Guidelines

    Battisti, N. M. L.; Mislang, A. R.; Cooper, L.; O'Donovan, A.; Audisio, R. A.; Cheung, K. L.; Sarrió, R. G.; Stauder, R.; Soto-Perez-de-Celis, E.; Jaklitsch, M.; more...
    Journal of Geriatric Oncology (2020)

    Fulltext@MSK | Save
  • Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
    Journal Article

    Voss, M. H.; Gordon, M. S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D. C.; Cervantes, A.; Puzanov, I.; Pili, R.; more...
    British Journal of Cancer (2020)

    Fulltext@MSK | Save
  • MILO/ENGOT-ov11: Binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
    Journal Article

    Monk, B. J.; Grisham, R. N.; Banerjee, S.; Kalbacher, E.; Mirza, M. R.; Romero, I.; Vuylsteke, P.; Coleman, R. L.; Hilpert, F.; Oza, A. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
    Journal Article

    Machiels, J. P.; Gomez-Roca, C.; Michot, J. M.; Zamarin, D.; Mitchell, T.; Catala, G.; Eberst, L.; Jacob, W.; Jegg, A. M.; Cannarile, M. A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum
    Journal Article

    Gershenson, D. M.; Bhosale, P.; Grisham, R. N.
    Gynecologic Oncology Reports (2020)

    Fulltext@MSK | Save
  • Single-arm, open-label, phase II study of LY3023414 for the treatment of recurrent or persistent endometrial cancer
    Meeting Abstract

    Rubinstein, M. M.; Hyman, D.; Caird, I.; O'Cearbhaill, R.; Grisham, R.; Tew, W.; Hensley, M.; Sabbatini, P.; Aghajanian, C.; Iasonos, A.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • A randomized phase II trial of secondary cytoreductive surgery (SCS) plus /- carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with recurrent platinum-sensitive ovarian cancer (EOC)
    Meeting Abstract

    Zivanovic, O.; Chi, D.; Zhou, Q.; Iasonos, A.; Makker, V.; Grisham, R. N.; Konner, J. A.; Diaz, J. P.; Brown, A. K.; Langstraat, C. L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase I/II study to evaluate systemic durvalumab plus intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results
    Meeting Abstract

    Zamarin, D.; Odunsi, K.; Slomovitz, B. M.; Duska, L. R.; Nemunaitis, J. J.; Reilley, M.; Bykov, Y.; Holland, A.; Hubbard-Lucey, V. M.; Shohara, L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC)
    Meeting Abstract

    Swisher, E. M.; Kristeleit, R. S.; Oza, A. M.; Tinker, A.; Ray-Coquard, I. L.; Oaknin, A.; Coleman, R. L.; Burris, H. A. 3rd; Aghajanian, C.; O'Malley, D. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Randomized phase II study of sapanisertib (SAP) plus paclitaxel (PAC) versus PAC alone in patients (pts) with advanced, recurrent, or persistent endometrial cancer
    Meeting Abstract

    Scambia, G.; Han, S. N.; Oza, A. M.; Colombo, N.; Oaknin, A.; Raspagliesi, F.; Wenham, R. M.; Braicu, E. I.; Jewell, A.; Makker, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save